

Curriculum Vitae – Thomas Engstrøm, professor, DMSci, PhD, FESC

Education and post-graduate degrees and certifications

1991 MD, University of Copenhagen
1998 PhD degree, University of Copenhagen
2003 DSci degree (doctor medicinae), University of Copenhagen
2004 Board certified specialist in cardiology
2016 Adjunct Professor, University of Aalborg, Denmark
2016 Guest Professor, Lund University, Sweden.
2016 Associate professor, clinical ambassador, University of Copenhagen
2018 Professor in invasive cardiology, University of Copenhagen

Copenhagen Jan 23, 2019



Present position

Professor at The Heart Centre Rigshospitalet, University of Copenhagen. Head of Department of Invasive Cardiology 2007-2016

Post-graduate courses

> 25 postgraduate courses in clinical and scientific medicine

Scientific impact and peer-reviewed publications

Cited 7109 times (without self-citation) with a H-index of 33 (i.e. 33 papers cited more than 33 times). There are 5 articles in the New England Journal of Medicine, 4 in The Lancet and 1 in JAMA. Total papers are 194 with 118 within the latest 5 years (Jan 2014 – Jan 2019).

Invited lectures

More than 75 invited lectures on national and international meetings.

Supervision and oppositions

PhD main supervisor: 5
PhD co-supervisor: 8
Post doc supervisor: 2
PhD opponent: 4
DMSci. opponent: 1

Late breaking clinical trial presenter

VERDICT; ESC 2018, DANAMI3-iPOST; American College of Cardiology 2016, DANAMI3-PRIMULTI; American College of Cardiology 2015 and EURO PCR 2015, POSTCON II; EURO PCR 2011, POSTCON; American College of Cardiology 2009 and EURO PCR 2009.

Research prizes

Awarded the Danish Cardiological Society Research Prize 2013
Ischemic Heart Disease Group awarded Global Excellence Prize 2013

Principal investigator randomized trials

Acuity study, FAME study, POSTCON I, FAME II study, POSTCON II (Founder and principal investigator), DANAMI 3-iPOST (Founder and steering comitté), DANAMI 3-DEFER (Founder and steering comitté), DANAMI 3-PRIMULTI (Founder and steering comitté), Leaders free study, Danegaptide (Founder and steering comitté), Prospect II (Steering comitté), Corsira study, FAME III study, Full Revasc (Steering comitté), DANSHOCK (Founder and steering comitté), Condi-2 (Steering comitté), IAMI, VERDICT (Steering Comitté)

Independent funding (in total > EURO 3 mio)

Total > EURO 4.5 mio from independent sources including The Danish Heart Foundation, Danish Council for Strategic Research (part of the Editors group) and Novo Nordisk Foundation.

Biotech collaboration funding (in total EURO 2.5 mio)

The Danegaptide Study in collaboration with Zealand Pharma A/S

Journal and foundation peer-review

A number of international journals and foundations including Circulation, JAMA cardiology, JACC, European Heart Journal, BMJ, The Lancet Global Health, American Heart Journal, The British Heart Foundation, The Health Research Board, Ireland

Scientific areas of special interest

- Myocardial protection in ischemic heart disease with special reference to reperfusion injury
- Clinical trial strategies in AMI with specific reference to testing of pivotal drug candidates
- The significance of pressure derived strategies in percutaneous coronary interventions.
- Receptor signaling in smooth muscle cells
- Multivessel disease in AMI
- Animal models in acute ischemia and reperfusion